ReShape Lifesciences Inc. (RSLS) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ReShape Lifesciences Inc. (RSLS) Bundle
Evaluate the financial outlook of ReShape Lifesciences Inc. (RSLS) like an expert! This (RSLS) DCF Calculator comes with pre-filled financials and offers you the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to match your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.1 | 11.3 | 13.6 | 11.2 | 8.7 | 7.7 | 6.8 | 6.1 | 5.4 | 4.8 |
| Revenue Growth, % | 0 | -25.12 | 20.36 | -17.35 | -22.79 | -11.22 | -11.22 | -11.22 | -11.22 | -11.22 |
| EBITDA | -17.2 | -18.1 | -60.6 | -24.9 | -14.5 | -7.7 | -6.8 | -6.1 | -5.4 | -4.8 |
| EBITDA, % | -114.15 | -160.15 | -445.71 | -221.75 | -166.92 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .9 | 1.7 | 2.0 | 2.2 | .2 | .9 | .8 | .7 | .6 | .5 |
| Depreciation, % | 5.92 | 14.75 | 14.49 | 19.15 | 1.77 | 11.22 | 11.22 | 11.22 | 11.22 | 11.22 |
| EBIT | -18.1 | -19.8 | -62.6 | -27.1 | -14.6 | -7.7 | -6.8 | -6.1 | -5.4 | -4.8 |
| EBIT, % | -120.07 | -174.9 | -460.21 | -240.91 | -168.69 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 2.9 | 3.0 | 22.8 | 3.9 | 4.5 | 3.6 | 3.2 | 2.8 | 2.5 | 2.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.1 | 2.6 | 2.8 | 2.2 | 1.7 | 1.7 | 1.5 | 1.3 | 1.2 | 1.0 |
| Account Receivables, % | 27.15 | 23.19 | 20.7 | 19.4 | 19.12 | 21.91 | 21.91 | 21.91 | 21.91 | 21.91 |
| Inventories | 1.3 | 2.2 | 3.0 | 3.6 | 3.7 | 1.9 | 1.7 | 1.5 | 1.4 | 1.2 |
| Inventories, % | 8.73 | 19.86 | 22.08 | 32.13 | 43.11 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 |
| Accounts Payable | 4.3 | 3.7 | 3.5 | 1.9 | 1.7 | 1.9 | 1.7 | 1.5 | 1.3 | 1.2 |
| Accounts Payable, % | 28.25 | 32.35 | 25.5 | 17.14 | 19.46 | 24.54 | 24.54 | 24.54 | 24.54 | 24.54 |
| Capital Expenditure | .0 | -.4 | -.4 | -.1 | .0 | -.1 | -.1 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | -0.09278282 | -3.45 | -2.59 | -1.17 | -0.49551 | -1.56 | -1.56 | -1.56 | -1.56 | -1.56 |
| Tax Rate, % | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 | -0.45876 |
| EBITAT | -17.9 | -19.6 | -62.5 | -26.9 | -14.7 | -7.7 | -6.8 | -6.0 | -5.4 | -4.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -18.2 | -18.4 | -62.0 | -26.4 | -14.4 | -4.9 | -5.9 | -5.3 | -4.7 | -4.2 |
| WACC, % | 8.5 | 8.51 | 8.52 | 8.51 | 8.52 | 8.51 | 8.51 | 8.51 | 8.51 | 8.51 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -19.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4 | |||||||||
| Terminal Value | -65 | |||||||||
| Present Terminal Value | -43 | |||||||||
| Enterprise Value | -63 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | -59 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | -574.14 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: ReShape Lifesciences Inc.'s (RSLS) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that tailors to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life RSLS Financials: Pre-filled historical and projected data for ReShape Lifesciences Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate ReShape’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize ReShape’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file containing ReShape Lifesciences Inc. (RSLS) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your decisions.
Why Choose ReShape Lifesciences Inc. (RSLS) Calculator?
- Comprehensive Tool: Offers robust analyses including market potential, cost-effectiveness, and patient outcomes.
- Customizable Inputs: Modify highlighted fields to explore different healthcare scenarios.
- Detailed Insights: Automatically computes the intrinsic value and projected growth of ReShape Lifesciences Inc. (RSLS).
- Preloaded Data: Access to historical performance and future projections for informed decision-making.
- Professional Quality: Perfect for healthcare analysts, investors, and medical consultants.
Who Should Use ReShape Lifesciences Inc. (RSLS)?
- Healthcare Investors: Make informed investment choices with cutting-edge insights into the medical device sector.
- Market Analysts: Streamline your research with comprehensive data on ReShape Lifesciences' product offerings.
- Consultants: Easily tailor presentations or reports focused on innovative weight loss solutions.
- Health Enthusiasts: Enhance your knowledge of bariatric products and their impact on patient care.
- Academics and Students: Utilize it as a valuable resource for studies in healthcare and medical technology.
What the Template Contains
- Historical Data: Includes ReShape Lifesciences Inc.'s (RSLS) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate ReShape Lifesciences Inc.'s (RSLS) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of ReShape Lifesciences Inc.'s (RSLS) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.